Abstract. Histamine is involved in different physiological and pathological responses, such as immune response, gastric acid secretion or neurotransmission, as either angiogenesis or cancer. Histidine decarboxylase (HDC) catalyzes the formation of histamine from histidine. HDC has been suggested as a new marker for neuroendocrine differentiation, inflammatory pathologies and several leukemia and highly malignant forms of cancer, such as melanoma and small cell lung carcinoma. In the present work, we describe the use of Syber Green-based quantitative real-time RT-PCR to determine the expression of histidine decarboxylase in human cells and tissue. As an internal control, glyceraldehyde 3-phosphate dehydrogenase was also amplified. The linear dynamic range of the assay covered 4 orders of magnitude for HDC amplification. The detection limit was 0.1 ng of total RNA extracted from HMC-1 cells. This method is simple, rapid, sensitive, and quantitative, and allows for the specific identification of cells and tissue expressing HDC, stressing its potential diagnostic usefulness in malignancies in which HDC is described as a new marker.
Introduction
The biogenic amine histamine plays a pivotal role in several physiological responses, including immune response, gastric acid secretion and neurotransmission, among others (1) . L-histidine decarboxylase (HDC) is the only enzyme that catalyzes the formation of histamine from L-histidine, which is expressed in the cell types involved in histamine production and secretion, including mast cells, monocytes/macrophages, basophils, enterochromaffin-like cells, and histaminergic neurons (1) . However, histamine is also involved in several pathological disorders, including angiogenesis and other inflammation-related processes, as well as cancer (1) (2) (3) . HDC has previously been shown to be overexpressed in human melanoma (4) , small cell lung carcinoma (5) , several types of neuroendocrine tumors (6, 7) and chondrocytes of arthritic cartilage (8) . It is also well documented that HDC is overexpressed in myelogenous leukemia lymphoblasts, mastocytomas and severe mastocytosis (9) (10) (11) . Therefore, HDC has been suggested as a new marker for neuroendocrine differentiation (6) and as a good diagnostic tool for inflammatory pathologies and highly malignant tumors (4) (5) (6) (7) (8) . Traditionally, HDC expression is detected by Northern or Western blot analysis, RT-PCR, or immunohistochemistry (4) (5) (6) (7) (8) 12, 13) . However, a reliable and automatizable quantitative method to determine HDC expression for use in the clinical analysis laboratory is urgently required.
The aim of the present study was to develop a protocol for the quantitative determination of HDC mRNA transcripts in human cells and tissue. As a reference source we used human HMC-1 mast cells, a cell line expressing high levels of HDC as revealed by Northern blotting. To fulfill our purpose, we next developed a real-time RT-PCR procedure. Unlike endpoint RT-PCR, real-time quantification is defined by C T (threshold cycle number) at a fixed threshold where PCR amplification is still in the exponential phase and the reaction components are not limiting gene amplification. We evaluated the pre-analytical conditions required for the use of HDC mRNA measurements as a diganostic tool in the clinical analysis laboratory. We analyzed relative standard curves (14, 15) . Additionally, we carried out parallel glyceraldehyde-3-phosphate dehydrogenase (GAPDH) reference gene expression determination, as a renormalization strategy. Finally, we tested the performance of the procedure by using samples of total RNA extracted from the human KU812F myelogenous leukemia lymphoblast cell line (expressing HDC) and two human tumor cell lines that do not express HDC, namely the HT-1080 fibrosarcoma and MDA-MB231 breast cancer cell lines. ONCOLOGY REPORTS 15: 193-197, 2006 Real-time RT-PCR analysis of human histidine decarboxylase, a new marker for several types of leukemia and cancer
Materials and methods
Cell culture. Human HMC-1 mast cells were kindly supplied by Dr J.H. Butterfield (Mayo Clinic, Rochester, MN, USA) and maintained in Iscove's medium supplemented with 10% calf serum, 2 mM glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin, 1.25 μg/ml amphoterycin, iron supplement and 1.2 mM ·-thioglycerol. These cells grow in suspension and their density was maintained at 0.1-1.5x10 6 cells/ml. Human KU812F myelogenous leukemia lymphoblast cells were supplied by the European Collection of Animal Cell Cultures and were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum, 2 mM glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin and 1.25 μg/ml amphoterycin. These cells grow in suspension and their density was maintained at 3-9x10 5 cells/ml. Human MDA-MB231 breast cancer and HT-1080 fibrosarcoma cells were obtained from the American Type Culture Collection. MDA-MB231 cells were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum, 2 mM glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin and 1.25 μg/ml amphoterycin. These adherent cells were subcultured twice a week at a 1/4 split ratio. HT-1080 cells were maintained in DMEM (containing glucose at 4.5 g/l) medium supplemented with 10% fetal calf serum, 2 mM glutamine, 50 U/ml penicillin, 50 μg/ml streptomycin and 1.25 μg/ml amphoterycin. These adherent cells were sub-cultured twice a week at a 1/5 split ratio.
RNA isolation. Total RNA from the different cells tested was extracted using the RNeasy mini kit (Qiagen) or the GenElute Mammalian Total RNA miniprep kit (Sigma). RNA was quantified and the quality tested by photometric measurement. We only used highly purified RNA (A 260 /A 280 >1.95).
Real-time RT-PCR.
Oligonucleotide primers for the amplification were designed using Amplify 1.2 software (16). The selected specific and optimal sequences, shown in Table I , were chosen to prevent amplification of genomic DNA. According to the suggestion to abandon the one enzyme/one tube protocols for real-time RT-PCR (17), we carried out two step RT-PCR. Reverse transcriptions were performed for 1 h at 42˚C in a final volume of 25 μl, containing 5 μg of total RNA (previously denaturated for 10 min at 65˚C), 1.3 mM dNTPs, 800 nM antisense primer and 200 units of MMLV-reverse transcriptase (Promega). PCRs were carried out in a final volume of 25 μl, containing 1 μM of both primers, 1x Syber Green supermix (Bio-Rad), and variable amounts of RT products. Thermal cycling was peformed in an iCycler iQ (Bio-Rad), evaluated as a very impressive instrument in a recent review on real-time RT-PCR for mRNA quantification (17) . Data were treated with the accompanying software iCycler iQ Optical System Software 3.0a. The program profile used for HDC amplification was: 95˚C for 3 min and 50 cycles of denaturation for 20 seconds at 95˚C, and annealing for 15 seconds at 58˚C and extension for 30 seconds at 72˚C. The program profile used for GAPDH was 94˚C for 3 min followed by 30 cycles of denaturation, annealing and extension for 30 sec each at 94˚C, 67.5˚C and 72˚C, respectively.
Results

HDC expression in HMC-1 cells.
RNA isolated from HMC-1 cells, as described above, was used to detect HDC mRNA by Northern blot analysis. As a probe, the RT-PCR product obtained with the oligos described in Table I and confirmed by sequencing was used. Fig. 1 shows that there was a high expression level of HDC in HMC-1. As previously reported, two HDC mRNA species were observed, which were supposed to be generated by alternative splicing (10, 18) .
Development af a quantitative assay for HDC mRNA. The characteristics of the assay were evaluated according to the guidelines for the validation of analytical procedures (19, 20) . From amplification curves for HDC and GAPDH ( Fig. 2A and B) , C T values at a fixed threshold of relative fluorescence were determined. Calibration curves were constructed by plotting C T values as a function of log of total RNA, assuming that RNA targets were reversed, transcribed, and subsequently amplified with similar efficiency (Fig. 2C and D) (17) . Amplification efficiencies were calculated from the slopes of linear regression curves according to the expression E=10
(-1/slope) , and were 2.620±0.176 for HDC and 2.110±0.161 for GAPDH. The linear dynamic range of the assay covered over 4 orders of magnitude for HDC and 5 orders of magnitude for GAPDH. Intra-assay CVs were <3% for HDC and <4% for GAPDH. Analysis of the melting curve profiles confirmed the specific accumulation of the amplification products (Fig. 3A and B) , with a single melting point for HDC (Tm= 89.0±0.2˚C) and a single melting point for GAPDH (Tm=83.0±0.2˚C). The Table I . List of primers used for HDC and GAPDH amplification.
Forward primer (5'-3' GCCCAAGGGAGATGATGGAG TGCACCACCAACTGCTTAGC
Reverse primer (5'-3') GGCTGGATGCCCAGGTGAAT GGCTGGACTGTGGTCATGAG Amplicon size (bp) 341 88  ----------------------------------------------------------------------------------------------------- detection limit based on visual evaluation was 0.1 ng of total RNA extracted from HMC-1 cells.
Expression of HDC mRNA in other cell lines.
The experimental procedure and the analytical model were therefore applied to test the performance of the assay in situations of clinical relevance. The goal was to test whether the procedure discriminates samples expressing or not expressing HDC. Total RNA samples extracted from a human tumor cell line expressing HDC (basophilic KU812F myelogenous leukemia lymphoblast cells), and two human tumor cell lines that do not express HDC, namely the HT-1080 fibrosarcoma and MDA-MB231 breast cancer cell lines, were used, along with samples from HMC-1, as internal positive controls. As observed in the melting curve profiles, there was a specific amplification of HDC in samples from ONCOLOGY REPORTS 15: 193-197, 2006 both the HMC-1 and KU812F cells, but there was no detectable amplification of HDC in samples from the HT-1080 and MDA-MB231 tumor cells (Fig. 4A) . However, as expected, there was a specific amplification of GAPDH in samples from all the test cell lines (Fig. 4B) . It should be underscored, however, that the melting point of the GAPDH amplification product obtained for samples from MDA-MB231 cells was slightly higher (Tm=84.0±0.2˚C) than that obtained for samples from the other three cell lines. The quantification of HDC signals normalized using the GAPDH signal as an internal standard was carried out according to the method described by Liu and Saint (21) . These ratio values were 5.30x10 -3 for HMC-1 and 5.58x10 -3 for KU812F cells.
Discussion
It is well established that HDC is expressed by mast cells and, therefore, mastocytosis show increased levels of the enzyme (10) . Severe mastocytosis and mastocytomas are considered to be oncologic diseases (11) . Previously, histidine decarboxylase has been described as a new marker for several leukemia and highly malignant forms of cancer, such as melanoma and small cell lung carcinoma (4-7). All these data underscore the importance of a reliable and automatizable quantitative method to determine HDC expression. However, up until now no such method was available. In this report, we describe a rapid, sensitive, specific, and quantitative assay to determine HDC mRNA levels in biological samples useful for determinations with potential diagnostic value in oncology.
